Stereotactic body radiation therapy (SBRT), defined as the delivery of >5Gy per fraction, has emerged as a well-established standard of care option for the definitive management of localized prostate ...
At a median follow-up of 19.6 months, the median PSA was 0.028 ng/mL. 18/100 patients developed biochemical recurrence, with a median time to recurrence of 10 months. The biochemical recurrence-free ...
The PCS5 trial is a Canadian multicenter, open-label, phase III randomized trial that included men with histologically proven, clinically localized prostate cancer with ≥1 high-risk feature (s) ...
This was a single-center, retrospective analysis of 42 patients with MIBC who underwent TMT at the Moffitt Cancer Center between October 2019 and April 2024 and had ≥1 post-TMT ctDNA (Signatera TM) ...
A total of 295 eligible patients were enrolled with a median follow-up of 5.0 years. The arms were well balanced, with a median age of 65 years (IQR 59-71), 50% with positive surgical margins, 51% ...
ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High-Risk Adenocarcinoma of ...
Artera Unveils Four Presentations at ASTRO 2025 Illustrating its Multimodal Artificial Intelligence (MMAI) Platform’s Scalability, Speed, and Potential to Personalize Treatment Decisions for Multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback